Write a Comment
15 Comments
I have Hep C geno type 3a. Just starting the process of getting treatment now that I have Medicare ABD, which will pay for treatment. Along the way I assume Hep C has been a major factor in my now having diabetes 2 (just found out) Just beginning Insulin treatment. Also I am sure Hep c is responsible for the Umbilical hernia I have that showed up about a year ago. So Diabetes treatment with Solvaldi + Interferon + Ribavirin sounds wicked for 12 weeks, but I did 24 wks before without the Solvaldi (virus undetected) for 18 weeks , but it came back. I am determined to beat this virus I have had for 42 yrs. I would rather endure the pain of 12 weeks rather than 24 weeks of Solvaldi and Ribavirin. Sounds very tricky doing Hep C treatment while have diabetes with wild swings of blood sugar, but that's the price. Always a price to pay. Still have to deal with the Hernia. Any feed back on having hernia operation before or after treatment??
I am so mad for you. This stuff irks me. Janice - have you tried resubmitting in 2016? I just read about a whole bunch of insurance plans that were rewritten to approve F0-F4 beginning this year. It may be worth going through this again. Also, the Hep C Careline has some very good advocates who may be able to help you - www.hepatitisc.pafcareline.org The one stumbling block is drug and alcohol use - I am opposed to those screening tests, but some companies are putting patients through the paces. Let me know if you have an success.
I have Hep C, genome 3, F-3 and Regence will NOT cover me OR ANYONE else. I have been through 3 appeals & they are just stalling & hoping I will die! Everyone should know there are a ton of lawsuits out there regarding there refusal to cover this life or death drug. I heard it is now in other counties. Is it possible to obtain at another country for less money if we must pay ourselves? Thanks, Janice
I had to read this twice since I was confused by what your pharmacist said. You are saying that the one with hep C who is being treated is your husband and not you, and he is NOT taking ribavirin. There is no indication, research, science, advice, or logic supporting what the pharmacist said. Your obgyn gave you good advice. Hope 2016 brings a baby and a hep-free husband.
Hi I am soon to be 42 and currently my husband and I are trying to have a baby. He was diagnosed and soon to start the 12 week course of •Daklinza is used with Sovaldi. my OBGYN told me we should be fine, however the pharmacist stated 'NO'. All that I see when I look into it is 'unknown' and statements saying to stay away from pregnancy are attached to ribavirin (which he is NOT taking). I feel like I am torn because that is waiting another 9 months to even start again, which I may not be able to due to age..... please advise hopeful
Thank you ! You are hired...
"Basically, Technivie is Viekira Pak with the dasabuvir." This should read: Technivie is Viekira Pak WITHOUT the dasabuvir.
Lucinda K. Porter, RN
I am curious as to why you think hep C is responsible for the hernia - that is a very unlikely connection, but I may be missing something here, and would love to know what your doc said. As for timing, this is something you and your doc need to work out, depending on which has the bigger priority. Something to consider - in July Gilead is bringing out a new drug that has high response rates for GT 3 and no ribavirin. Here's what I wrote about it: Article: Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection - G.R. Foster, et al. NEJM November 16, 2015 Gist of the Study: Two phase 3 studies of untreated and previously treated subjects with chronic hep C GT 2 or 3 infection, including those with compensated cirrhosis. In one trial, hep C GT 2 subjects received a single sofosbuvir/velpatasvir (SOF/VEL) combo tablet (134 subjects) or sofosbuvir plus ribavirin (SOF/RBV 132 subjects) once daily for 12 weeks. In the other trial, hep C GT 3 subjects received either a single SOF/VEL combo tablet (277 subjects) or SOF/RBV (275 subjects) once daily for 12 weeks. Bottom Line: In the GT 2 study, the SVR rate in SOF/VEL group was 99 percent; SOF/RBV was 94 percent. In the GT 3 study, the SVR rate in SOF/VEL group was 95 percent; SOF/RBV was 80 percent. Discussion: The most common adverse events in the two studies were fatigue, headache, nausea, and insomnia. In the two studies, one participant dropped out early because of an adverse event. He reported anxiety, headache, and difficulty concentrating on the first of the study.
January 21, 2016